Matches in Wikidata for { <http://www.wikidata.org/entity/Q91894844> ?p ?o ?g. }
Showing items 1 to 47 of
47
with 100 items per page.
- Q91894844 description "article scientifique (publié 2020)" @default.
- Q91894844 description "articolo scientifico (pubblicato il 2020)" @default.
- Q91894844 description "artigo científico (publicado na 2020)" @default.
- Q91894844 description "artikull shkencor i botuar më 01 janar 2020" @default.
- Q91894844 description "artículo científico publicado en 2020" @default.
- Q91894844 description "artículu científicu espublizáu en xineru de 2020" @default.
- Q91894844 description "im Januar 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q91894844 description "scientific article published on 01 January 2020" @default.
- Q91894844 description "wetenschappelijk artikel" @default.
- Q91894844 description "наукова стаття, опублікована 1 січня 2020" @default.
- Q91894844 description "научна статия" @default.
- Q91894844 name "Improved response rates shown with neoadjuvant and adjuvant pembrolizumab for triple-negative breast cancer with lymph node involvement" @default.
- Q91894844 name "Improved response rates shown with neoadjuvant and adjuvant pembrolizumab for triple-negative breast cancer with lymph node involvement" @default.
- Q91894844 name "Improved response rates shown with neoadjuvant and adjuvant pembrolizumab for triple-negative breast cancer with lymph node involvement" @default.
- Q91894844 type Item @default.
- Q91894844 label "Improved response rates shown with neoadjuvant and adjuvant pembrolizumab for triple-negative breast cancer with lymph node involvement" @default.
- Q91894844 label "Improved response rates shown with neoadjuvant and adjuvant pembrolizumab for triple-negative breast cancer with lymph node involvement" @default.
- Q91894844 label "Improved response rates shown with neoadjuvant and adjuvant pembrolizumab for triple-negative breast cancer with lymph node involvement" @default.
- Q91894844 prefLabel "Improved response rates shown with neoadjuvant and adjuvant pembrolizumab for triple-negative breast cancer with lymph node involvement" @default.
- Q91894844 prefLabel "Improved response rates shown with neoadjuvant and adjuvant pembrolizumab for triple-negative breast cancer with lymph node involvement" @default.
- Q91894844 prefLabel "Improved response rates shown with neoadjuvant and adjuvant pembrolizumab for triple-negative breast cancer with lymph node involvement" @default.
- Q91894844 P1433 Q91894844-C1107C7B-D24C-40C8-8A94-4108F9525A83 @default.
- Q91894844 P1476 Q91894844-8CB2242E-7525-40FD-B76D-154A250E3CA2 @default.
- Q91894844 P2093 Q91894844-F9E5D270-00EE-496E-9E5B-1B064100FB13 @default.
- Q91894844 P304 Q91894844-0B34D3AB-D631-4F9E-971F-A404F081C676 @default.
- Q91894844 P31 Q91894844-2D17D7F3-2DA0-4293-9C33-83A8D64D0C15 @default.
- Q91894844 P356 Q91894844-13009C5F-4918-41A7-804D-79E11ADA9F15 @default.
- Q91894844 P433 Q91894844-F7051F2C-3F6E-4189-9E70-7EFF40495C83 @default.
- Q91894844 P478 Q91894844-BB03FE91-311F-4DEB-9998-4384F8E0E2F7 @default.
- Q91894844 P577 Q91894844-D1EDA911-A143-4A57-AA87-2B5CE39964C9 @default.
- Q91894844 P698 Q91894844-CAB1C93A-0FC7-41C7-AEF5-D7C0B66192BE @default.
- Q91894844 P921 Q91894844-CD7A89A9-E9D5-45F3-A6BF-E04198230E8C @default.
- Q91894844 P921 Q91894844-DC5B75BB-E689-4D23-8F11-D5F8EA4323F2 @default.
- Q91894844 P356 CNCR.32894 @default.
- Q91894844 P698 32286699 @default.
- Q91894844 P1433 Q326041 @default.
- Q91894844 P1476 "Improved response rates shown with neoadjuvant and adjuvant pembrolizumab for triple-negative breast cancer with lymph node involvement" @default.
- Q91894844 P2093 "Carrie Printz" @default.
- Q91894844 P304 "1827" @default.
- Q91894844 P31 Q13442814 @default.
- Q91894844 P356 "10.1002/CNCR.32894" @default.
- Q91894844 P433 "9" @default.
- Q91894844 P478 "126" @default.
- Q91894844 P577 "2020-01-01T00:00:00Z" @default.
- Q91894844 P698 "32286699" @default.
- Q91894844 P921 Q13896859 @default.
- Q91894844 P921 Q7843332 @default.